OBJECTIVE: To assess the significance of lipoprotein(a) [Lp(a)], a risk factor for atherothrombosis, and its relationship with fibrinolysis in a cohort of patients with antiphospholipid syndrome (APS). METHODS: Plasma levels of Lp(a) were measured in 68 patients with APS (42 primary, 26 secondary to systemic lupus erythematosus). RESULTS: Elevated plasma levels of Lp(a) were found in patients with APS compared to 22 healthy controls (p = 0.0001). The significance persisted after comparing Lp(a) levels in 3 APS subgroups (arterial thrombosis, n = 37; venous thrombosis, n = 31; recurrent miscarriages, n = 24) with those of controls (p < 0.0001). Patients with APS with maximal elevation of Lp(a) showed a lower fibrinolytic activity (lower D-dimer and higher plasminogen activator inhibitor) than patients whose Lp(a) was within a normal range. CONCLUSION: These findings suggest that Lp(a) may represent a marker of APS and that Lp(a) has a negative effect on the fibrinolytic system that might contribute to the thrombotic tendency of APS.
OBJECTIVE: To assess the significance of lipoprotein(a) [Lp(a)], a risk factor for atherothrombosis, and its relationship with fibrinolysis in a cohort of patients with antiphospholipid syndrome (APS). METHODS: Plasma levels of Lp(a) were measured in 68 patients with APS (42 primary, 26 secondary to systemic lupus erythematosus). RESULTS: Elevated plasma levels of Lp(a) were found in patients with APS compared to 22 healthy controls (p = 0.0001). The significance persisted after comparing Lp(a) levels in 3 APS subgroups (arterial thrombosis, n = 37; venous thrombosis, n = 31; recurrent miscarriages, n = 24) with those of controls (p < 0.0001). Patients with APS with maximal elevation of Lp(a) showed a lower fibrinolytic activity (lower D-dimer and higher plasminogen activator inhibitor) than patients whose Lp(a) was within a normal range. CONCLUSION: These findings suggest that Lp(a) may represent a marker of APS and that Lp(a) has a negative effect on the fibrinolytic system that might contribute to the thrombotic tendency of APS.
Authors: Aneel A Ashrani; Michel K Barsoum; Daniel J Crusan; Tanya M Petterson; Kent R Bailey; John A Heit Journal: Thromb Res Date: 2015-04-11 Impact factor: 3.944
Authors: Hong Wang; Chan E Hong; Joshua P Lewis; Yanbei Zhu; Xing Wang; Xin Chu; Joshua Backman; Ziying Hu; Peixin Yang; Christopher D Still; Glenn S Gerhard; Mao Fu Journal: G3 (Bethesda) Date: 2016-11-08 Impact factor: 3.154
Authors: Rustem I Litvinov; Rosa M Nabiullina; Laily D Zubairova; Mileusha A Shakurova; Izabella A Andrianova; John W Weisel Journal: Front Immunol Date: 2019-07-16 Impact factor: 7.561